AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy | MicrobiomeTrials← Back to trialsNCT06063850
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2024-06-12Est. Completion: 2026-11-30
Enrollment target: 12 participants Locations- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Mayo Clinic Arizona, Phoenix, Arizona, United States
- Stanford University, Palo Alto, California, United States
- Mayo Clinic Florida, Jacksonville, Florida, United States
- Kansas University Medical Center, Kansas City, Kansas, United States
- Johns Hopkins School of Medicine, Baltimore, Maryland, United States
- Midatlantic Epilepsy and Sleep Center, Bethesda, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Corewell Health, Grand Rapids, Michigan, United States
- Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
- Northeast Regional Epilepsy Group, Hackensack, New Jersey, United States
- Robert Wood Johnson Hospital, New Brunswick, New Jersey, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Ohio State University, Columbus, Ohio, United States
- Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Allegheny Health Network, Pittsburgh, Pennsylvania, United States
Other microbiome trials you might be interested in
Epilepsy
This is a phase I study (Protocol: UX-GIP001-102) investigating UX-GIP001 Injection, a novel cell therapy product consis…
Beijing, ChinaEst. completion Jul 1, 2029
Mesial Temporal Lobe Epilepsy
This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve c…
Birmingham, United StatesEst. completion Feb 2029
Baylor Scott & White Medical Center, Austin, Texas, United StatesMedical College of Wisconsin, Milwaukee, Wisconsin, United States